IPO Year: 2023
Exchange: NASDAQ
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
MIAMI, FL / ACCESSWIRE / September 11, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing innovative therapies for neurologic and neuropsychiatric disorders, announced today that it has selected neuropathic pain as the initial and primary indication for its novel oral ketamine analog, Ketamir-2. The company has submitted a request for a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) and anticipates the meeting to occur in November 2024. All ongoing regulatory IND-enabling studies are advancing smoothly, and MIRA remains on track to submit its IND to the FDA by the end of this year, wit
Study Highlights Superior Efficacy of Ketamir-2 Over Oral Ketamine, Achieving Full Normalization of Pain ThresholdsMIAMI, FL / ACCESSWIRE / August 26, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is proud to announce a major breakthrough in the treatment of neuropathic pain. A recent pre-clinical study in rats demonstrated that its novel oral ketamine analog, Ketamir-2, produced a significant reversal of neuropathic pain, induced by nerve ligation, culminating in a 100% normalization of pain thresholds at the highest dose. This effect stands in stark contrast to traditional ketamine, which proved ineffective orally under th
MIAMI, FL / ACCESSWIRE / August 19, 2024 / MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) "MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company, is pleased to provide a comprehensive update on its recent achievements and scientific advancements as it nears a crucial milestone: the submission of its Investigational New Drug (IND) application by the end of the year. This update highlights the company's strategic progress, significant scientific breakthroughs, and the expertise driving its innovative drug candidates toward clinical trials.Recent Company HighlightsLeadership Enhancement with Dr. Itzchak AngelMIRA has strengthened its leadership by appointing Dr. Itzchak Angel as
This breakthrough in bioavailability and formulation showcases the potential for advanced, at home neurological treatments.MIAMI, FL / ACCESSWIRE / August 12, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), or MIRA Pharmaceuticals, a leading pre-clinical-stage pharmaceutical company unveiled new preclinical data providing further insights into the mechanism of action of its innovative drug candidate, Ketamir-2's principal metabolite, Nor-Ketamir-2. This data indicates that similar to Ketamir-2, its principal metabolite, Nor-Ketamir-2 selectively interacts with a low affinity at the NMDA PCP site with high selectivity and lack of activity on the glutamate NMDA site, opiate and other sites. A
Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Out of respect and privacy for Dr. Chapman's family, details of his passing will not be made available. Telomir's Boar
Latest positive preclinical data provides another step in the path to potential IND submission this year for novel ketamine analog MIAMI, FL / ACCESSWIRE / July 25, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company, today announced new insights garnered from additional, recently received preclinical study data regarding the mechanism of action and toxicology data for its novel oral ketamine analog, Ketamir-2.Ketamir-2 is MIRA's drug candidate being investigated as a potential treatment for neurological and neuropsychiatric disorders. The new preclinical study results announced today are the latest in a string of pos
New findings highlight potential advantages of MIRA's novel oral ketamine analog for treating neurological and neuropsychiatric disorders MIAMI, FL / ACCESSWIRE / July 22, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company, today announced new preclinical study results for its novel oral ketamine analog, Ketamir-2.The additional data announced today continues a string of promising preclinical results announced by MIRA in recent months for Ketamir-2 as MIRA works towards its goal of submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the end of this year which, if
Testing confirms MIRA's preliminary beliefs regarding potential treatment for neurological and neuropsychiatric disorders MIAMI, FL / ACCESSWIRE / July 15, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical development company, today announced promising new findings from recent preclinical studies of its novel oral pharmaceutical marijuana analog, MIRA-55, which is being studied as a potential treatment for anxiety and cognitive decline.The new data confirms MIRA's earlier beliefs regarding MIRA-55's pharmacological profile and potential for potency and efficacy. Importantly, however, the new preclinical data compared MIRA-55 direct
New preclinical studies suggest that, unlike traditional ketamine, MIRA's oral ketamine analog Ketamir-2 does not induce hyper-locomotor activity, indicative of psychotic symptoms, offering the potential for safer mental health treatments MIAMI, June 24, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, today announced new compelling preclinical results for its investigational compound, Ketamir-2, a novel oral ketamine analog. The new data highlights Ketamir's potential to provide therapeutic benefits without inducing schizophrenia-
The positive results from this preclinical study underscore Ketamir-2's potential as a superior alternative to traditional ketamine Unlike ketamine, which requires intravenous or intranasal administration, Ketamir-2's oral formulation promises ease of use and better patient compliance and is not a controlled substance under DEA rules MIAMI, June 10, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, today announced positive preclinical study results highlighting the potential efficacy and safety profile of Ketamir-2, MIRA's novel oral ketami
8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
EFFECT - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
10-Q/A - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
10-Q - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
S-3 - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
DEFA14A - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
DEF 14A - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Out of respect and privacy for Dr. Chapman's family, details of his passing will not be made available. Telomir's Boar
Ketamir-2, the Company's novel oral ketamine analog in development, aims to provide a safe and effective alternative for managing cancer pain and associated depression MIAMI, May 21, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced it is in advanced discussions with Memorial Sloan Kettering Cancer Center (MSK) to initiate a preclinical study evaluating MIRA's novel oral ketamine analog, Ketamir-2, for the treatment of cancer-related pain and depression. MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collabo
A seasoned pharmaceutical industry executive with over 40 years at the forefront of innovation, including at Synthelabo (acquired by Sanofi-Aventis), Dr. Angel aims to propel MIRA Pharmaceuticals' mission to tackle unmet needs in neurologic and neuropsychiatric disorders MIAMI, March 21, 2024 /PRNewswire/ -- MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on the development of novel treatments for neurologic and neuropsychiatric disorders, proudly announces the appointment of distinguished pharmaceutical executive Dr. Itzchak Angel as its new Chief Scientific Advisor. Dr. Angel brings over 40 years of preclin
Latest positive preclinical data provides another step in the path to potential IND submission this year for novel ketamine analog.
Shares of Comcast Corporation (NASDAQ:CMCSA) fell sharply during Tuesday's session after the company reported worse-than-expected second-quarter sales results. Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from Benzinga Pro. Comcast shares declined 6.1% to $37.12 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Azitra, Inc. (NYSE:AZTR) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office grant
Shares of SAP SE (NYSE:SAP) rose sharply in today's pre-market trading after the company reported second-quarter financial results. SAP reported quarterly earnings of 82 cents per share which missed the analyst consensus estimate of $1.19 per share. Quarterly sales came in at $8.92 billion which missed the analyst consensus estimate of $8.96 billion, representing an 8.81% increase over sales from the same period last year, according to data from Benzinga Pro. SAP shares gained 5.9% to $212.34 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Nature’s Miracle Holding Inc. (NASDAQ:NMHI) rose 183.4% to $0.9779 in pre-market trading after fal
U.S. stocks traded higher toward the end of trading, with the NASDAQ Composite gaining around 300 points on Monday. The Dow traded up 0.19% to 40,362.58 while the NASDAQ rose 1.70% to 18,027.77. The S&P 500 also rose, gaining, 1.09% to 5,564.74. Check This Out: Top 4 Real Estate Stocks That May Fall Off A Cliff This Quarter Leading and Lagging SectorsInformation technology shares jumped by 1.7% on Monday. In trading on Monday, energy shares fell by 0.2%. Top Headline Verizon Communications Inc (NYSE:VZ) shares fell around 6% on Monday after it reported fiscal second-quarter results. Its sales increased 0.6% year over year to $32.8 billion, marginally missing the analyst
Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell downgraded the stock from Buy to Neutral. CrowdStrike shares dipped over 11% on Friday after the company suffered a major outage impacting businesses around the world. Selective Insurance Group shares dipped 13.2% to $264.65 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares climbed 148% to $1.98 after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. CareMa
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded down 0.03% to 40,276.45 while the NASDAQ rose 0.81% to 17,870.43. The S&P 500 also rose, gaining, 0.51% to 5,533.14. Check This Out: Top 4 Real Estate Stocks That May Fall Off A Cliff This Quarter Leading and Lagging SectorsInformation technology shares jumped by 0.9% on Monday. In trading on Monday, energy shares fell by 0.5%. Top Headline Verizon Communications Inc (NYSE:VZ) shares fell around 6% on Monday after it reported fiscal second-quarter results. Its sales increased 0.6% year over year to $32.8 billion, marginally missing the
https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_07222024_MIRA_Sorensen.pdf
MIRA Pharmaceuticals Inc (NASDAQ:MIRA) announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. MIRA Pharmaceuticals is developing the next generation of oral ketamine and pharmaceutical marijuana analogs to treat neurologic neuropsychiatric disorders. The additional data comes as MIRA prepares to submit an Investigational New Drug (IND) application to the FDA by the end of this year. Ketamir-2 is under investigation for its potential to treat neurological and neuropsychiatric disorders, including depression, treatment-resistant depression, and post-traumatic stress disorder. Ketamir-2 has demonstrated in in vitro studies that it is not a substrate
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 1% on Monday. Following the market opening Monday, the Dow traded up 0.37% to 40,436.13 while the NASDAQ rose 1.10% to 17,921.40. The S&P 500 also rose, gaining, 0.72% to 5,544.40. Check This Out: Top 4 Real Estate Stocks That May Fall Off A Cliff This Quarter Leading and Lagging SectorsInformation technology shares jumped by 1.3% on Monday. In trading on Monday, energy shares fell by 0.2%. Top Headline The Chicago Fed National Activity index fell to 0.05 for June, versus previous reading of 0.23. However, analysts were expecting a reading of -0.09. Equities Trading UP